Humanization: Exciting Emerging Technologies Within Drug Discovery
With recent demand to reduce the cost and time of the drug discovery process, big pharma and biotech start-ups are investing in a human-focused approach
15th July 2016
Changes came into effect at the end of June transforming the way pharmaceutical companies in Europe work with healthcare professionals (HCPs) and healthcare organisations (HCOs).
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has introduced a new disclosure code, requiring companies to disclosure any transfers of value (whether in cash, in kind or otherwise) provided to HCPs and HCOs.
Partnerships between the pharma industry, and HCPs/HCOs is arguably vital in helping to bring new medicines to market. The new obligations aim to provide greater transparency and dialogue on the ethics behind payments made by pharma to doctors.
In the UK, payments are disclosed on the Association of the British Pharmaceutical Industry’s (ABPI) publically available database Disclosure? UK, which so far details all payments made in the 2015 calendar year.
What does Disclosure UK reveal?
The database shows payments from 109 pharmaceutical companies, revealing £340.3 million paid to support activities ranging from:
What does this mean?
As the new code (quietly) came into force last month, many companies are suddenly faced with the reality of meeting minimum transparency requirements. A couple of points for companies to consider:
There is also the consideration of public trust with the industry and individual doctors – as even the perception of a conflict of interest could have damaging effects. Whether this happens is yet to be seen – much of this will depend on if we see a small drip-feed of payment related articles over the summer.
It is going to take years of PR and communication (internal and external) so the public and media does not misinterpret legitimate payments to HCPs and HCOs from pharma companies – and understand the importance of such partnerships.